Refined DRGs: trials in Europe
Related Experiment Video
Updated: Oct 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
1Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH 03756.
Abstract:
DRGs have recently been revised to account for severity of illness through a more refined use of additional diagnoses (comorbidities and complications). Under the refined model, patients are differentiated with respect to classes of additional diagnoses that are disease and procedure specific. The Refined DRGs were evaluated with data from selected Barcelona hospitals and the findings compared to those obtained with Norwegian and English hospital discharge information. In terms of predictive performance, the Refined DRGs represent only a very small improvement over the second revision DRGs for the study's sample of European data. This lack of significant improvement is likely attributed to misclassification of the European discharges due to limited reporting of additional diagnoses. It is recommended that European countries use the Refined DRGs as a descriptive framework for reporting utilization statistics in order to encourage more complete reporting of comorbidities and complications.
More Related Videos
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
07:36Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Therapeutic Drug Monitoring: Drug Analysis Methods